Reference of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate《Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?》 was published in 2021. The authors were Stachulski, Andrew V.;Taujanskas, Joshua;Pate, Sophie L.;Rajoli, Rajith K. R.;Aljayyoussi, Ghaith;Pennington, Shaun H.;Ward, Stephen A.;Hong, Weiqian David;Biagini, Giancarlo A.;Owen, Andrew;Nixon, Gemma L.;Leung, Suet C.;O’Neill, Paul M., and the article was included in《ACS Infectious Diseases》. The author mentioned the following in the article:
A review. The rapidly growing COVID-19 pandemic is the most serious global health crisis since the Spanish flu of 1918. There is currently no proven effective drug treatment or prophylaxis for this coronavirus infection. While developing safe and effective vaccines is 1 of the key focuses, a number of existing antiviral drugs are being evaluated for their potency and efficiency against SARS-CoV-2 in vitro and in the clinic. We review the significant potential of nitazoxanide (NTZ) as an antiviral agent that can be repurposed as a treatment for COVID-19. Originally, NTZ was developed as an antiparasitic agent especially against Cryptosporidium spp.; it was later shown to possess potent activity against a broad range of both RNA and DNA viruses, including influenza A, hepatitis B and C, and coronaviruses. Recent in vitro assessment of NTZ has confirmed its promising activity against SARS-CoV-2 with an EC50 of 2.12μM. We examine its drug properties, antiviral activity against different viruses, clin. trials outcomes, and mechanisms of antiviral action from the literature to highlight the therapeutic potential for the treatment of COVID-19. Furthermore, in preliminary PK/PD analyses using clin. data reported in the literature, comparison of simulated TIZ (active metabolite of NTZ) exposures at 2 doses with the in vitro potency of NTZ against SARS-CoV-2 gives further support for drug repurposing with potential in combination chemotherapy approaches. The review concludes with details of 2nd generation thiazolides under development that could lead to improved antiviral therapies for future indications.2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) were involved in the experimental procedure.
2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been approved as an orphan drug for the treatment of diarrhea in children (age, 1–11 years) and is associated with giardiasis, but it also is approved for diarrhea caused by crytosporidiosis in patients with AIDS.Reference of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate
Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica